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Summary The combination of heat and chemotherapy was studied in an intraperitoneal tumour model. Rats
bearing peritoneal CC531 tumours (2-6 mm) were treated i.p. with cDDP or CBDCA [maximal tolerated dose
(MTD)] in combination with regional hyperthermia (41.5°C, 1 h) of the peritoneal cavity. The addition of
hyperthermia to the i.p. treatment led to a decrease in the MTD of cDDP by 33.3% at 41.5C. This was due
to increased nephrotoxicity. The MTD of CBDCA did not change as a result of hyperthermia treatment. The
chemo-hyperthermia treatment resulted in more cDDP or CBDCA DNA adducts in peritoneal tumours after
the combined treatment than after chemotherapy alone. The increased tumour platinum concentrations, rising
from 1.3 1ig Pt g'l tumour at 37°C to 5.4fig Pt g- tumour at 41.5C for cDDP and from 0.2 fig Pt g' tumor
to 0.7 Lg Pt g- tumour at 41.5C for CBDCA, contributed considerably to the enhanced numbers of cDDP
or CBDCA DNA adducts. As a result of the latter, i.p. chemotherapy combined with regional hyperthermia
led to an increase in tumour growth delay (TGD) after increasing the temperature to 41.5C for cDDP and
CBDCA (by 40 days for cDDP, 22 days for CBDCA). These data were in agreement with the in vitro findings,
i.e. that higher temperatures led to increased cytotoxicity.
In ovarian cancer, a tumour that remains largely confined to
the peritoneal cavity for most of its natural history, there is
both experimental and clinical evidence for a fairly steep
cytotoxic dose-response curve to a number of
chemotherapeutic agents (Alberts et al., 1985; Levin &
Hryniuk, 1987). Over the past decade the potential benefits
and limitations of i.p. drug delivery have been defined and
taken into consideration in the development of clinical trials.
One of the basic principles ofi.p. treatment is the free surface
diffusion of the drug into the tumour (Los et al., 1989, 1990).
It is therefore critical that the drug actually reaches the
tumour (Dunnick et al., 1979; Howell et al., 1982). The
determining factor is the penetration of the drug into the
tumour. This issue has been examined extensively for several
cytostatic drugs (Ozols et al., 1979; West et al., 1980; Kerr &
Kaye 1987; Los et al., 1990). The universal conclusion of
these studies has been that, in spite of the high local drug
concentrations achieved in the peritoneal cavity after i.p.
treatment, the direct penetration of cytostatic drugs from the
peritoneal cavity into the tumour is limited, ranging from
several cell layers to 1-3 mm from the peritoneal surface (los
& McVie 1991).
In view of this limited pentration capacity of cytostatic
drugs, the efficacy of the i.p. treatment will probably also
depend on the drug delivered by the systemic circulation. In
essence only i.p.-administered drugs for which the dose-
limiting toxicity is systemic will show no reduction in the
amount of drug reaching the tumour by capillary flow.
cDDP and CBDCA, for example, both have systemic side-
effects after i.p. treatment, limiting the amount of drug that
can be administered (Howell et al., 1982; Elferink et al.,
1988). Pharmacokinetic studies in rodents and patients have
demonstrated that tumour exposure by the systemic circula-
tion is similar after i.v. or i.p. administration of cDDP or
CBDCA (Ten Bokkel Huinink, 1985; Elferink et al., 1988;
Los et al., 1989, 1991a). Since the pharmcokinetic studies,
clinical studies on response have suggested that i.p. therapy is
an acceptable option for patients with persistent residual
ovarian cancer who fail to respond to systemic treatment.
Patients with microscopic disease or with lesions <0.5cm
appear to experience prolonged disease-freee survival follow-
ing i.p. chemotherapy (Markman, 1991). However, even in
this subgroup patients will finally relapse.
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A potential way of improving the efficacy of i.p.
chemotherapy is the application of hyperthermia during i.p.
chemotherapy. The rationale behind this approach is the
observations that heat induces ultrastructural changes in cell
membranes (Arancia et al., 1989), will increase membrane
transport of drugs (Hahn et al., 1975) and can alter cellular
metabolism (Hahn & Shiu, 1983), which can lead to an
increased drug uptake into tumour tissue (Los et al., 1991b,
1992). Furthermore, in vitro studies have demonstrated
enhanced cytotoxicity of cDDP and CBDCA by hyperther-
mia (Fisher & Hahn, 1982; Herman et al., 1988).
In view of the potentiating effects of heat on the cDDP
and CBDCA cytotoxicity, and in addition to previous phar-
macokinetic studies performed in a peritoneal tumour model
(Los et al., 1991b, 1992), we have tested the efficacy of
regional hyperthermia during i.p. treatment for tumours
restricted to the peritoneal cavity. We therefore assessed the
cDDP or CBDCA DNA adduct formation in peritoneal
tumours and, most importantly, the tumour growth delay of
peritoneal tumours in our tumour model in the rat after i.p.
treatment with cDDP or CBDCA combined with regional
hyperthermia. This led to an evaluation of the role of
regional hyperthermia of the abdominal cavity in i.p. treat-
ment of cancers restricted to the peritoneal cavity.
Materials and methods
Rats anddrugs
Male WAG/Rij rats (8-12 weeks old; 250-300 g) were
obtained from the animal department of The Netherlands
Cancer Institute. The animals were kept in a temperature-
controlled room on a 12 h light-12 h darkness schedule and
fed standard rat chow and tap water ad libitum. cis-
Diamminedichloroplatinum(II) (cDDP) and cis-diammine
(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) were
obtained from Bristol Myers (Weesp, The Netherlands).
cDDP- and CBDCA-containing vials were stored at room
temperature.
Tumor model
The tumour used (CC531) is a well-defined transplantable rat
colonic adenocarcinoma (Marquet et al., 1984), with an in
vitro doubling time of 16 h. The tumour also grows in vivo
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when implanted subcutaneously and intraperitoneally. (Los
et al., 1989). In vitro, cells were cultured under 5% carbon
dioxide in 75 cm2 flasks (Falcon, Oxnard, USA) containing
Dulbecco's modified Eagle medium (DMEM, Irvine, UK)
and 10% fetal calf serum (FCS, Gibco). Cells were subcul-
tured after reaching a density of 5 x 106 175 cm-2 by tryp-
sinisation and replated at a density of 105 cells 175cm2.
Drug uptake studies were performed in a multiple
peritoneal tumour model (tumour size: 2-5 mm in diameter).
For this purpose rats were inoculated i.p. with 2 x 106 CC531
tumour cells. Four weeks after inoculation small tumour
nodules were present on the diaphragm, peritoneum and the
mesothelium between the intestines. Treatment was started 30
days after inoculation of the tumour cells.
Growth delay studies were performed in a single peritoneal
tumour model in the WAG/Rij rat. A tumour disc, with a
diameter of 2.5 mm and a thickness of 2.5 mm, was
implanted by a Haemoclip fixation on either the inside of the
ventral abdominal wall or the adipose tissue surrounding the
spermatic cord. At day 10 after implantation rats were
treated. For assessing peritoneal tumour growth new
laparotomies were performed every 2 weeks.
Hyperthermia treatment
Rats were anaesthetised by i.m. injection of 0.05 ml
(6 mg kg-') Rompun followed by 50 mg kg-' Ketalar 12 min
later. Then the rats were positioned in a thermostatically
controlled water bath at 41.5°C and cDDP or CBDCA was
administered i.p. in a 0.9% sodium chloride solution at a
temperature of 41.5°C (20 ml). The temperature in the
peritoneal cavity of the animal steadily increased from
around 39°C to 41.5°C in about 30 min. The duration of the
heat treatment at 41.5°C was 60 min. During treatment, i.p.
temperatures were monitored every 5 min using copper-
constant thermocouple probes (IT-18, diameter 0.62 mm,
Sensortek, USA) at three locations in the peritoneal cavity
(near the bladder, the spleen and right kidney). In addition to
the temperatures in the peritoneal cavity, the rectal
temperature at a distance of 6 cm from the anal ring and the
intraoesophageal temperature were monitored.
Toxicity studies
Toxicity studies were performed in order to determine the
MTD for cDDP and CBDCA in combination with regional
hyperthermia. The doses for cDDP were 3, 3.5, 5 and 7 and
2, 3.5 and Smg kg' at 37°C and 41.5°C respectively. The
CBDCA dose was 30 mgkg-' at both 37°C and 41.5°C. The
MTD for CBDCA at normal body temperature is 30 mg
kg-' (Los et al., 1993a). Since nephrotoxicity and myelosup-
pression are dose limiting, we determined plasma creatinine
levels and the nadir for thrombocytes, leucocytes and eryth-
rocytes and used these data together with weight loss to
determine the MTD. At fixed time points (day 0, 5, 7, 10, 14,
up to 52 days), blood samples were taken and creatinine,
thrombocyte, leucocyte and erythrocyte levels were deter-
mined.
Determination oftumourplatinum concentrations
Rats with multiple peritoneal tumours (2-5 mm in diameter)
were treated i.p. with cDDP (3.5 or 5 mg kg-') or with
CBDCA (30 mg kg-') with or without adbominal hyperther-
mia. After 24 h tumours were collected and prepared for
platinum measurements.
A Varian model AA40 atomic absorption spectrometer
with a GTA 96 graphite tube atomiser (with Zeeman back-
ground correction) was used for analysis. Sample preparation
and the fast atomic absorption spectrometry procedure have
been described elsewhere (Los et al., 1990).
Immunocytochemical assay
Peritoneal tumours were fixed in Kryofix (Merck, Darmstadt,
Germany) and embedded into K-plast (Medin, Giessen, Ger-
many). Two-micron sections were cut and mounted on slides,
coated with a solution of chromium(III)-potassium sulphate
(0.1%) and gelatin (1%). The immunocytochemical proce-
dure was carried out essentially as described by Terheggen et
al. (1987). Briefly the staining procedure was as follows:
sections were treated with methanol-hydrogen peroxide (to
inactivate endogenous peroxidase) and ethanol-sodium hyd-
roxide (to denature the DNA and/or to increase the acces-
sibility to antibodies). Non-specific binding of the anti-cDDP
DNA serum (NKI-A59) antibody was prevented by adding
calf thymus (CT) DNA (Boehringer, Mannheim, Germany)
to the incubation. The NKI-A59 antibodies bound to the
DNA in the last step were visualised by double staining.
The characteristics of the rabbit antiserum NKI-A59
against cDDP-modified calf thymus DNA (platinum-nucleo-
tide ratio 6.7 x 10-2) have been described by Terheggen et al.
(1991). NKI-A59 (applied without further purification), goat
anti-rabbit immunoglobulin (Campro Benelux, Elst, The
Netherlands) and rabbit PAP complex (American Qualex, La
Miranda, USA) were used at dilutions of 1:2,500 1:600 and
1:3,000 respectively. All sera were diluted in phosphate buffer
(pH 7.4) containing 10 mM potassium dihydrogen phosphate/
140 mM sodium chloride, 10% normal goat serum (NGS)
and 0.04% Triton X-100 (BDH, Poole, UK). The nuclear
staining intensity of nuclei in selected areas (40 x 40gim) was
analysed and quantified with a Knott (Munich, Germany)
light-measuring device with beam diameter of 5 gim, which
was coupled to a Leitz Orthoplan microscope. Data were
analysed by an Atari ST computer (Sunnyvale, USA) prog-
rammed with a version of the histochemical data acquisition
system (Hidacsys; Microscan, Leiden, The Netherlands;
Scherer et al., 1988). The integrated optical density of a
selected area was expressed in arbitrary units. In each slide
the nuclear staining density of ten randomly selected areas,
corresponding to 10-20 nuclei each, was measured.
Sensitivity ofCC531 to cDDP and CBDCA
The sensitivity of CC531 cells to cDDP and CBDCA at
different temperatures was tested by clonogenic assay. CC531
cells were harvested as described before and counted. Cells in
a single-cell suspension were plated in six-well tissue culture
clusters (Costar, Cambridge, UK) at 150 cells per well in
conditioned medium. After 24 h of incubation at 37C, the
cells being attached to the plates, 2fig ml-' cDDP (IC40) or
100 gg ml-' CBDCA (ICm) was added. The culture clusters
were incubated at 370C, 38.5°C, 400C, 41.50C or 43°C for
75 min (15 min was needed to reach the proper temperature).
After incubation, cells were washed twice with phosphate-
buffered saline (PBS) and 3 ml of fresh medium was added.
All plates were returned to the incubator and incubated for
7-10 days for the development of colonies. Colonies were
fixed with ethanol, stained with crystal violet for 10min,
counted and related to the control.
Tumour growth delay
Rats with a small solid tumour (4-5 mm in diameter) in the
peritoneal cavity were treated i.p. with 3.5 mg kg-' cDDP at
37C, with 2.8 mg kg- cDDP at 40°C, 41°C and 41.50C or
with 30mg kg-' CBDCA at 37°C, 40°C, 40.50C and 41.50C.
The tumour was located on the peritoneal wall left of the
median close to the transitions of the upper and lower quad-
rants or on adipose tissue surrounding the spermatic cord
high in the pelvis. Tumour measurements were performed
every 2 weeks by laparotomy. The tumour size was assessed
by measuring the three perpendicular diameters of the
tumour with digital calipers. The geometric mean of the three
values was then calculated (Begg, 1987). Tumour growth
delay was defined as the time required to regrow to a
predetermined size (mean diameter of 10 mm) of the treated
group minus the control group. The growth delay ratio
(GDR) was calculated by the TGD at a certain temperature
divided by the TGD at 37°C.TUMOUR GROWTH DELAY DURING THERMOCHEMOTHERAPY 237
Statistics
Student's t-test or the Wilcoxon test were used to study
differences; P-values <0.05 were considered to indicate
significant differences.
Results
Toxicity studies
Toxicity studies were performed in order to determine the
MTD of i.p. cDDP or CBDCA treatment combined with
hyperthermia of the peritoneal cavity (41.5°C). Since neph-
rotoxicity and myelosuppression are most prominent and
dose limiting, plasma creatinine levels and the nadir oferyth-
rocytes, leucocytes and thrombocytes were used to determine
the MTD for cDDP and CBDCA treatment respectively.
Increasing the temperature from 37°C to 41.5°C resulted in
increased plasma creatinine levels after cDDP treatment
(Figure 1). MTD or cDDP at 37C was 5 mgkg-' with a
plasma creatinine level of 320 ± 69 ng ml-'. A dose reduction
of 33.3% (3.5 mg kg-') at 41.5°C was required to obtain
similar creatinine levels as those at 37°C (Figure 1). For
CBDCA the nadir of erythrocytes, leucocytes and throm-
bocytes was determined (Table I). It was shown that in spite
of a decrease in the nadir of thrombocytes no dose reduction
was necessary. Thrombocyte counts reached normal values
after 50 days, after a nadir (down to 106 x I091') around
day 10.
DNA adductformation andplatinum concentration in
peritoneal tumours
The cDDP and CBDCA adducts in peritoneal tumours were
determined after normothermic and hyperthermic treatment
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Figure 1 Nadir of serum creatinine levels, 5-7 days after i.p.
treatment with cDDP at normothermia (37°C, -@-) or hyperther-
mia (41.5°C, -O-).
Table I Nadir of blood cells after CBDCA (30 mg kg-') treatment
combined with regional hyperthermia
37°C 37°C 41.5°C
Cells control CBDCA CBDCA
Leucocytes (x I0 I-') 10.4± 3.4 5.0± 2.4 6.3 ± 2.5
Erythrocytes (x 1012 1-1) 7.9 ± 0.5 4.1 ± 3.5 5.9 ± 0.3
Thrombocytes (x1091-') 659±243 351±200 106±53*
n = five rats ± s.d. The nadir was reached 7-11 days after treatment;
measurements were performed at day 5, 7, 10, 14 up to 52 days.
Data presented in this table represent measurements performed on
day 7 and 10 (no significant differences between treatments at 37°C
and 41.5°C, except for thrombocytes, *P<0.05).
with i.p. cDDP and CBDCA (Figure 2). An increase in
cDDP or CBDCA DNA adducts was detected after hyper-
thermic treatment. After cDDP treatment the staining den-
sity, a measure of the adduct formation, increased from 20
arbitrary units (a.u.) at body temperature up to 54 a.u. after
hyperthermic treatment. The signal after CBDCA treatment
at body temperature was not detectable, whereas after hyper-
thermic treatment the staining intensity was well above the
detection limit (30 a.u.).
In addition to the DNA adducts measurements, and in an
attempt to explain the increased DNA adduct formation, the
platinum concentrations in the same tumours were deter-
mined. Higher platinum concentrations were achieved with
hyperthermic treatment than after normothermic treatment
with 5 mg kg-' cDDP, i.e. 5.4 vs 1.3 jLgg-' tumour tissue. At
equitoxic doses, 5mg kg-' for the normothermic treatment
and 3.5 mg kg-' for the hyperthermic treatment, 2.2 times
more platinum was detected after hyperthermic treatment
(2.9 vs 1.3 jig g-' tissue). Platinum concentrations in tumours
after CBDCA treatment were three times higher after hyper-
thermic treatment than after normothermic treatment, i.e. 1.5
vs 4.5 jig g-
I tumour tissue (Figure 3).
Cytotoxicity in vitro
The effect of temperature on the cytotoxicity of cDDP and
CBDCA was shown in vitro using a clonogenic assay, CC531
cells were incubated with cDDP and CBDCA (approximately
the IC50 values) at different temperatures, ranging from 37°C
to 43°C. Figure 4 shows the relative decrease in survival at
different temperatures, expressed as a percentage of the sur-
vival at 37°C. A relatively small increase in temperature to
38.5°C enhanced cytotoxicity of cDDP significantly. In con-
trast, an increase in temperature from 37°C to 40°C seems to
have less effect on the cytotoxicity of CBDCA. For the latter
drug temperatures of 41.5°C and higher were necessary to
increase cell kill effectively (Figure 4).
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Figure 2 Nuclear staining density in peritoneal tumour sections
(2 im) after normothermic (unshaded bar) or hyperthermic
(shaded bar) treatment with i.p. cDDP (3.5 mg kg-') or CBDCA
(30 mg kg-'). Tissue sections were stained for cDDP or CBDCA
DNA adduct formation. Each bar represents the mean ± s.d. of
at least ten randomly selected areas in two independently stained
tumour sections with 10-20 nuclei in each area. The increase in
DNA adduct formation between normothermic and hyperthermic
treatment for both cDDP and CBDCA is significant (P<0.001).
ND, not detectable.238 G. LOS et al.
Tumour response
The effect of regional hyperthermia on the peritoneal tumour
growth was studied up to 50 days after heat treatment.
Figure 5 demonstrates the tumour size at fixed time points
after heat treatment. It is clear that a single heat treatment
with temperatures up to 41.5°C does not affect tumour
growth. However, tumour growth delay of peritoneal
tumours was induced after i.p. treatment with both cDDP
and CBDCA at different temperatures (Figure 6). Tumour
growth delay was determined when tumours had reached
four times the initial size (geometric mean of 10mm). For
this purpose tumour growth was followed for 63 days. An
Figure 5 Effect of temperature on growth delay of peritoneal
tumours after hyperthemic treatment at 37°C (LC1), 40°C
( M ), 41°C ( 1} ) and 41.5°C ( M ). Each bar represents the
mean ± s.d. of the geometric mean of at least five tumours.
Figure 3 Platinum concentrations in peritoneal tumours after
i.p. cDDP or CBDCA treatment with or without regional hyper-
thermia of the peritoneal cavity. cDDP dose at 37°C was
Smgkg-' ( 1), at 41.5°C 5mgkg-' ( ) or 3.5 mgkg-'
( 1l1), equimolar and equitoxic with the normothermic treat-
ment. CBDCA dose was 30 mg kg-' at both 37C (LIII) and
41.5°C ( _ ).
45
Temperature (°C)
Figure 4 The relative decrease in survival of CC531 cells after
treatment with the IC40 of cDDP (2 gLgml-', -0-) and the IC50 of
CBDCA (100 gig ml-', -*-) at different temperatures, ranging
from 37°C up to 43°C. Survival was determined by clonogenic
assays.
Figure 6 Growth delay of peritoneal tumours after i.p. treat-
ment with cDDP or CBDCA at 37°C (-O-, control), 37°C (-A-,
3.5mgkg-' cDDP or 30mgkg-' CBDCA), 40°C (-V-, 2.8mg
kg-' cDDP or 30mgkg-' CBDCA), 410C (-0-, 2.8mgkg-'
cDDP or 30mg kg-' CBDCA), 41.5°C (---, 2.8 mgkg ' cDDP
or 30 mg kg- ' CBDCA). Each data point represents the mean of
2-4 independent experiments, with a total number of tumour-
bearing animals of six or more (geometric mean ± s.e.m.).
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Table II Tumour growth delay
Tumour growth delaja at
Drugs 37C 40°C 41°C 41.5°C
cDDP 4 ± 4 13 ± 2 19 ± la >40b
CBDCA 6 ± 8 6 ± 5 18 ± 12a 22±lOb
aTumour growth delay (days ± s.d.) was determined in at least two
independent experiments (n>4) and defined as the time (days)
required to regrow to a predetermined size (mean diameter 10 mm)
after treatment with either cDDP, 3.5 mg kg-' or 2.8 mg kg-' at
37°C or 40°C and above respectively, or CBDCA (30 mgkg-').
n = at least four tumour-bearing rats. bTGD differs significantly
compared with the treatment at 37°C (Wilcoxon test, P<0.05).
increase in the temperature from 3TC to 40°C led to tumour
growth delay of 4 ± 4 to 13 ± 2 days after cDDP treatment
(Table II). A further increase of the temperature to 41.5°C
resulted in a growth delay of more than 40 days, resulting in
a growth delay ratio (TGD 41.5°C/TGD 37C) of more than
10. Also, for CBDCA a similar pattern of tumour growth
delay is demonstrated (Figure 6, Table II). Tumour growth
delay increased from 6 ± 8 at 37C up to 22 days at 41.5°C,
resulting in a GDR of 3.6. These data indicate that cDDP
treatment is potentiated to a greater extent than CBDCA
treatment by temperatures in the range of 40-41.5°C.
Discussion
In previous studies we have shown that i.p. chemotherapy
with cDDP or CBDCA in combination with abdominal
hyperthermia leads to pharmacokinetic changes, higher
uptake of cDDP or CBDCA into peritoneal tumours and
higher cytotoxicity in vitro, using equimolar drug concentra-
tions at 37C and 41.5°C. In addition to these findings, we
now demonstrate that i.p. chemo-hyperthermia with cDDP
or CBDCA at MTD levels leads to increased cDDP and
CBDCA DNA adducts in peritoneal tumours and conse-
quently to an increase in peritoneal tumour growth delay.
It is demonstrated that abdominal hyperthermia can be
consistently and safely achieved and maintained in the rat
using a simple heating system (Los et al., 1991b, 1992). The
only disadvantage of this heating system is that a relatively
large part of the rat body is heated in the water bath (Los et
al., 1991b). This method results in a higher systemic
temperature than in other animals models (Spratt et al.,
1980; Zakris et al., 1987), which is certainly lower than that
achieved with whole-body hyperthermia (Riviere et al., 1986;
Wondergem et al., 1988). The higher systemic temperatures
obtained in our rat model seemed to increase nephrotoxicity
more than myelosuppression (Figure 1, Table I). This might
be explained by the fact that the kidney lies in the heated
area and, since the whole-body temperature is also raised, the
blood will cool down the well-perfused tissues less than at
normal body temperature. The increased temperature in the
peritoneal cavity consistently led to enhanced nephrotoxicity
(Wondergem et al., 1988; Los et al., 1991b). A dose reduction
of cDDP was, therefore, unavoidable. In situ heating of the
peritoneal cavity by a more regional approach than used in
our system will probably provide a small increase in systemic
temperature not exceeding the arterial temperature. Extensive
thermometry in patients treated with i.p. CBDCA in com-
bination with abnominal hyperthemia demonstrated that
regional hyperthermia delivered by the annular phase and
amplitude-controlled applicator led to peritoneal tumour
temperatures up to 42°C, while the systemic temperature did
not increase above 38.5°C (Formenti et al., 1992). This
clinical study demonstrates that local temperatures in the
peritoneal cavity can be raised while systemic temperatures
show only a minor increase. Recently we demonstrated in the
same model that the increase in platinum concentration in
normal tissues after the combined treatment remained behind
of that in tumours. Except in the kidney, in the case of
cDDP treatment combined with hyperthermia, no other
severe increase in tissue platinum concentration resulting in
toxicity could be observed (Los et al., 1991b, 1992).
At elevated temperatures the structure of biomembranes
can be altered drastically since membrane lipids and proteins
are in dynamic equilibrium with each other. The physical
state of the lipid component of the membrane may have
significant effects on the properties of the proteins and as
such modulate their conformation and activity (Konings et
al., 1988). Increasing the temperature may result in an in-
creased permeability of the cell membrane (Arancia, 1989).
This may partly explain the increased platinum concentra-
tions in peritoneal tumours after i.p. cDDP or CBDCA
treatment combined with regional hyperthermia of the
peritoneal cavity in this study. Since the pharmacokinetic
profiles of cDDP and CBDCA are also altered, it is not
excluded that an increase in tumour exposure also cont-
ributes to the higher intratumoral platinum concentrations.
However, in vitro studies with CC531 carcinoma cells have
also demonstrated increased intracellular platinum concentra-
tions after incubation with cDDP or CBDCA at higher
temperatures, supporting the increased permeability
hypothesis (Los et al., 1991b). In addition, previous in vitro
work has demonstrated that temperatures in the range of
37-41.5°C do not affect the binding of either cDDP or
CBDCA to isolated salmon sperm DNA in solution (Los et
al., 1993b), indicating that the binding per se of cDDP and
CBDCA to DNA is not influenced by increased temper-
atures. Therefore, it is likely that the increased platinum
concentrations found in peritoneal tumour after hyperther-
mia treatment resulted in higher levels of cDDP and CBDCA
DNA adducts. cDDPDNA adducts were also detectable after
cDDP treatment at 37°C, although the staining density for
the CBDCA DNA adducts did not exceed the detection limit
of this immunocytochemical method after normothermic
treatment. This difference is probably due to the lower hydra-
tion rate of CBDCA compared with cDDP. It is known that
the hydration rate of CBDCA can be as much as 100 times
lower than that of cDDP (Knox et al., 1986), resulting in a
lower DNA binding for the same molar exposure concentra-
tion.
As a result of the higher intratumoral platinum concentra-
tions and the increased platinum DNA adducts, chemo-
hyperthermia treatment showed an enhanced anti-tumour
response compared with chemotherapy alone. At two
different sites in the peritoneal cavity, namely on the
peritoneal wall and on adipose tissue surrounding the sper-
matic cord located high in the pelvis, increased tumour
growth delay was shown after raising the temperature. Com-
paring the tumour growth delay induced by cDDP or
CBDCA in combination with abdominal hyperthermia, one
may conclude that the tumour growth delay after cDDP
treatment increased with a small increase in temperature,
whereas higher temperatures were required for CDBCA
(Table II). These findings in the animal model corresponded
with the in vitro observations. Cytotoxicity after CBDCA
treatment (IC50 dose) increased significantly at 41.5°C and
above, while cytotoxicity of cDDP (IC40 dose) increased at
38.5°C, indicating different degrees of potentiation for cDDP
and CBDCA at an IC40/50 dose. In an additional experiment
at 42°C (data not shown), potentiation of CBDCA reached
the same level as cDDP at 41.5°C. This confirmed the sugges-
tion that CBDCA needs higher temperatures than cDDP for
the potentiation of its cytotoxic effect.
For i.p. therapy to show an advantage over i.v. therapy,
the drug is required to diffuse inward from the periphery into
the intraperitoneal tumour mass. By combinding ip. cDDP
or CBDCA chemotherapy with abdominal hyperthermia one
would expect a better penetration capacity of the cytostatic
drug. We hypothesise therefore that one of the factors
involved in the increase in intratumoral platinum concentra-
tion, resulting in an increase in tumour growth delay for both
cDDP and CBDCA, is better penetration of cDDP and
CBDCA into tumour tissue. This hypothesis is partly sup-
ported by previous work in which the spatial platinum dis-240 G. LOS et al.
tribution in peritoneal tumours after i.p. cDDP treatment at
41.5°C was more homogeneous than after treatment at 370C
(Los et al., 1991b). However, such an effect was not demon-
strated for CBDCA. Previous work has demonstrated that
abdominal hyperthermia augments intratumoral platinum
concentrations regardless of whether CBDCA is delivered i.p.
or i.v. (Los et al., 1992). Nevertheless, a rationale for pursu-
ing the i.p. route for CBDCA was given by concerns over
possible enhanced nephrotoxicity. It was demonstrated that
Pt concentrations in the kidney are increased more after i.v.
chemo-hyperthermia treatment than after i.p. chemo-
hyperthermia (Los et al., 1992).
In addition, other groups have now shown that hyperther-
mia increases the cytotoxicity of several chemotherapeutic
agents, such as nitrogen mustard, cisplatin (cDDP), carbo-
platin (CBDCA), bleomycin and mitomycin (Hahn, 1979;
Barlogie et al., 1980; Dahl, 1988). Fujimoto et al. (1988)
observed in an in vivo model of gastric cancer xenotrans-
planted into nude mice that hyperthermia plus mitomycin C
led to a delay in tumour growth and a significantly greater
effect on DNA synthesis than hyperthermia alone. The same
group also demonstrated that gastric cancer patients with
peritoneal dissemination treated with an intraperitoneal
hyperthermic perfusion with mitomycin C had a longer
disease-free survival period than after systemic mitomycin C
alone (Kokubun et al., 1991). Taking into account the
relative magnitude of the effects on tumours and normal
tissues, no tissues other than the kidney seem to be negatively
affected. Previous findings together with those presented in
the present study suggest that the combination of
chemotherapy and hyperthermia may be beneficial.
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